NASDAQ:INO Inovio Pharmaceuticals (INO) Stock Price, News & Analysis $0.77 -0.16 (-16.89%) Closing price 10/29/2026 04:00 PM EasternExtended Trading$0.86 +0.09 (+11.17%) As of 06:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About Inovio Pharmaceuticals Stock (NASDAQ:INO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Inovio Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.61▼$0.9750-Day Range$0.77▼$1.4352-Week Range$0.56▼$2.72Volume9.57 million shsAverage Volume4.09 million shsMarket Capitalization$79.80 millionP/E RatioN/ADividend YieldN/APrice Target$3.17Consensus RatingModerate Buy Company Overview Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells. Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases. The company has also developed INO-4800, an investigational DNA vaccine candidate for COVID-19. Its technology platform includes CELLECTRA, a proprietary device and electroporation system designed to improve the delivery of DNA medicines. Founded in 1983 as Genetronics, the company adopted the name Inovio Pharmaceuticals in 2009. Inovio is headquartered in Plymouth Meeting, Pennsylvania, and conducts research and clinical development activities through collaborations and trials in the United States and other international markets. Its products remain primarily investigational and are subject to regulatory review.AI Generated. May Contain Errors. Read More Inovio Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreINO MarketRank™: 2.63690630677 of 5 starsInovio Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat, and ranked 509th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingInovio Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialInovio Pharmaceuticals has a consensus price target of $3.17, representing about 310.3% upside from its current price of $0.77.Amount of Analyst CoverageInovio Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Inovio Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($0.72) to ($0.44) per share.Price to Book Value per Share RatioInovio Pharmaceuticals has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Inovio Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.96% of the float of Inovio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInovio Pharmaceuticals has a short interest ratio ("days to cover") of 6.94.Change versus previous monthShort interest in Inovio Pharmaceuticals has recently increased by 2.34%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInovio Pharmaceuticals does not currently pay a dividend.Dividend GrowthInovio Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.58 News SentimentInovio Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Inovio Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest17 people have searched for INO on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows11 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders1.70% of the stock of Inovio Pharmaceuticals is held by insiders.Percentage Held by Institutions26.79% of the stock of Inovio Pharmaceuticals is held by institutions.Read more about Inovio Pharmaceuticals' insider trading history. Receive INO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INO Stock News HeadlinesAfter $80M court judgment, Inovio could get even better news from the FDAOctober 29 at 7:15 AM | bizjournals.comInovio Awaits FDA Decision On INO-3107 For Rare Respiratory DiseaseOctober 28 at 10:47 AM | rttnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 30 at 1:00 AM | Weiss Ratings (Ad)Certain Common Stock of Inovio Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-OCT-2026.October 28 at 4:45 AM | marketscreener.comMInovio Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:INO)October 23, 2026 | americanbankingnews.comPiper Sandler Keeps Their Buy Rating on Inovio Pharmaceuticals (INO)October 22, 2026 | theglobeandmail.comInovio Says it Secured Favorable Judgment in VGXI, GeneOne LitigationOctober 20, 2026 | finance.yahoo.comINOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life ScienceOctober 20, 2026 | prnewswire.comSee More Headlines INO Stock Analysis - Frequently Asked Questions How have INO shares performed this year? Inovio Pharmaceuticals' stock was trading at $1.74 on January 1st, 2026. Since then, INO shares have decreased by 55.6% and is now trading at $0.7718. How were Inovio Pharmaceuticals' earnings last quarter? Inovio Pharmaceuticals, Inc. (NASDAQ:INO) released its earnings results on Wednesday, August, 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. Read the conference call transcript. When did Inovio Pharmaceuticals' stock split? Inovio Pharmaceuticals's stock reverse split on Thursday, January 25th 2024.The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Inovio Pharmaceuticals' major shareholders? Inovio Pharmaceuticals' top institutional shareholders include Green Alpha Advisors LLC (0.11%), LexAurum Advisors LLC (0.09%) and Prime Capital Investment Advisors LLC (0.07%). View institutional ownership trends. How do I buy shares of Inovio Pharmaceuticals? Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inovio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inovio Pharmaceuticals investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Advanced Micro Devices (AMD), NVIDIA (NVDA), NIO (NIO) and Gilead Sciences (GILD). Company Calendar Last Earnings8/12/2026Today10/30/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 INO's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INO CIK1055726 Webwww.inovio.com Phone(858) 410-3134Fax267-440-4242Employees112Year Founded1979Price Target and Rating Average Price Target for Inovio Pharmaceuticals$3.17 High Price Target$4.00 Low Price Target$2.50 Potential Upside/Downside+310.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$84.95 million Net MarginsN/A Pretax MarginN/A Return on Equity-669.94% Return on Assets-73.97% Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio1.00 Sales & Book Value Annual Sales$60 thousand Price / Sales1,330.07 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book2.14Miscellaneous Outstanding Shares103,400,000Free Float101,640,000Market Cap$79.80 million OptionableOptionable Beta1.61 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:INO) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMissed SpaceX’s 1,000% winner? Then this is for you…In 2024, SpaceX began ordering from a tiny supplier called Filtronic. Its stock has since climbed more than 1,...Brownstone Research | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredTrump’s $16 Trillion Chess Move (signed and highlighted)A newly signed executive order could point to one of the largest resource deals in history, according to Matt ...Monument Traders Alliance | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredDO YOU LIVE HERE? ⬇️Data centers now number about 1,300 across the US, with another 2,500 planned. Each can draw as much power as ...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
